CN102406645A - Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms - Google Patents
Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms Download PDFInfo
- Publication number
- CN102406645A CN102406645A CN2010102888033A CN201010288803A CN102406645A CN 102406645 A CN102406645 A CN 102406645A CN 2010102888033 A CN2010102888033 A CN 2010102888033A CN 201010288803 A CN201010288803 A CN 201010288803A CN 102406645 A CN102406645 A CN 102406645A
- Authority
- CN
- China
- Prior art keywords
- tumor
- kidney
- renal
- carcinoma
- purposes according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a purpose of an arylurea derivative in preparing a medicine for treating kidney neoplasms. The arylurea derivative is 1-(4-(trifluoromethyl)-phenyl)-3-(3-(6-(1-methyl-4-pyrazolyl)-4-pyrimidinyloxy-6-fluoro-phenyl)carbamide. The medicine of the invention has functions of inhibiting the growth of kidney neoplasms and incidence rate of pulmonary metastasis, in addition, the medicine has low toxic and side effect.
Description
Technical field
The present invention relates to the new purposes that Arylurea derivatives is used to prepare treatment tumor of kidney medicine, belong to the new purposes technical field of chemical compound.
Background technology
Tumor of kidney can be divided into two major types according to age of onset and anatomicopathological characteristics: 1. child's tumor of kidney: be called embryoma of kidney, before occurring in 3 years old mostly more.According to statistics, this tumor of kidney accounts for 20% of child's malignant tumor.The tumor of kidney of 2. being grown up: be common in more than 40 years old, the male is more than the women.The cancerous protuberance that betides excess of the kidney matter is called the carcinoma of renal parenchyma, and the cancerous protuberance that betides renal pelvis is called carcinoma of renal pelvis.
Much more very renal carcinoma is claimed renal cell carcinoma again, and renal adenocarcinoma originates from renal cells, can betide any position of excess of the kidney matter, but to see that minority is invaded and holonephros with upper and lower; Left and right kidney morbidity has equal opportunities, and the bilateral pathological changes accounts for 1%-2%.
The cancerous cell type is mainly clear cell carcinoma, granular cell carcinoma and undifferentiated carcinoma etc., is common with clear cell carcinoma wherein.The clear cell carcinoma volume is big, and edge clear is polygon, examine little and even, dyeing is dark; The cell quality is transparent color more.Cell often is arranged in lamellar, mamillary or tubulose.Granular cell is rounded, polygon or irregular form, dead color; Be full of tiny granule in the Cytoplasm, the kytoplasm amount is few; Nuclear is engrain slightly.Half renal carcinoma has above 2 kinds of cells simultaneously approximately.Also have the higher renal carcinoma of a kind of grade malignancy, its cell of carcinoma mesonephric is fusiformis, and nuclear differs more greatly or greatly less, has more karyokinesis to resemble, and is the sarcoma spline structure, is called undifferentiated carcinoma.
Medicine commonly used has vincaleucoblastine, methotrexate, bleomycin, vincristine, amycin, BCG, the pregnant preceding ketone of methyl acetaldehyde oxygen, hydroxyurea etc. in the chemotherapy of renal carcinoma.Clinical efficacy is not very desirable at present.
Summary of the invention
The present invention relates to the purposes that formula I chemical compound is used to prepare antitumor drug, treat the purposes of the medicine of tumor of kidney especially for preparation.
WO2007076473 discloses formula I chemical compound in 2007:
And mentioned the purposes of this chemical compound as the raf inhibitors of kinases.The Chinese named of formula I chemical compound is: 1-(4-(trifluoromethyl)-phenyl)-3-(3-(6-(1-methyl-4-pyrazolyl)-4-2-pyrimidinyl oxy)-6-fluoro-phenyl) urea.
The inventor is surprised to find, and formula I chemical compound is having unexpected outstanding effect aspect the treatment tumor of kidney.
Term used herein " treatment " refers to offer the mammal that the suffers from oncosis formula I chemical compound with effective dose, and purpose is to suppress growth of tumor in these animal bodies, eradicate tumor or tumor remission.
Term used herein " tumor of kidney " has comprised usually said tumor of kidney and renal carcinoma.
More common clinically tumor of kidney has: renal carcinoma (being derived from excess of the kidney matter), nephroblastoma, mamillary tumor (the renal pelvis renal calices takes place).Renal carcinoma: become human malignant lesion's middle kidney tumor only to account for about 1% 50～60 years old age occurred frequently of renal carcinoma.Man's prevalence is two times of women prevalence.Condition of illness is hematuria, lump, pain.The overwhelming majority is a renal carcinoma in adult's tumor of kidney.Nephroblastoma: be the modal abdominal tumor of children's.In children's's malignant tumor, nephroblastoma accounts for more than 20%.Tumor of renal pelvis: the age of onset great majority are at 40～70 years old, average 55 years old.Man's prevalence is two times of women prevalence.Early stage performance: intermittent painless gross hematuria, accidental cause clot stop up ureter and renal colic occurs, swollen thing of normal nothing or pain.Wherein common with renal cell carcinoma, be transitional cell carcinoma of renal pelvis and nephroblastoma secondly.
Renal carcinoma originates from renal cells, and recent research shows that Distal convoluted tubule and collecting tubule also possibly participated in the generation of renal carcinoma.Much more extremely renal carcinoma can take place at any position of excess of the kidney matter, but to see up and down at kidney.Its histological type mainly contains clear cell carcinoma, granular cell carcinoma and undifferentiated carcinoma etc., and is the most common with clear cell carcinoma.Clear cell is circle or multiangular, and volume is big, edge clear, and the little and engrain of nucleus, Cytoplasm is transparent, and this is because of being rich in glycogen and lipid in the Cytoplasm, dissolved causing in section and dyeing course.Granular cell carcinoma is circle, polygon or irregular form, is full of tiny granule in the Cytoplasm, and Cytoplasm is less, and grade malignancy is higher.But this tumor cell individualism of two types also can come across in the same tumor simultaneously, can form the Combination renal carcinoma.The kidney undifferentiated cancer cell is fusiformis, and karyokinesis is mutually more, is the sarcoma spline structure, and grade malignancy is higher.
Renal carcinoma of the present invention or tumor of kidney can be the tumor of kidney of classifying on clinically various or the pathology, for example: from the tumor of excess of the kidney matter, renal adenoma and renal carcinoma (claiming renal cell carcinoma again) are arranged; From the tumor of renal pelvis epithelium, the papilloma of dividing a word with a hyphen at the end of a line, transitional cell carcinoma, squama shape cell carcinoma and adenocarcinoma; From the tumor of kidney embryonal tissue, nephroblastoma (being the Wilms tumor), embryonal carcinoma and sarcoma are arranged; From the tumor of mesenchymal tissue, fibroma, fibrosarcoma, lipoma, liposarcoma, leiomyoma and leiomyosarcoma are arranged; Tumor from blood vessel has hemangioma, lymphoma and hamartoma; Tumor from nervous tissue has neuroblastoma, sympathoblastoma; From the tumor of kidney peplos, fibroma, leiomyoma, lipoma, mixed tumor are arranged; Cyst has isolatism cyst, multiple cyst, cystadenoma, dermoid cyst, cystadenocarcinoma; Metastatic tumo(u)r etc.
The inventor has carried out a large amount of screenings through a large amount of pharmacology pharmacodynamic tests to the Arylurea derivatives with the effect of raf inhibitors of kinases.Through pharmacology pharmacodynamic research, the discovery that the inventor is surprised, formula I chemical compound is having unexpected outstanding effect aspect the treatment renal carcinoma.The compounds of this invention has the effect of obvious suppression tumor growth, particularly suppresses the effect of renal carcinoma tumor growth, and The compounds of this invention obviously suppresses the lung metastasis rate, and The compounds of this invention has lower toxic and side effects.
Owing to generally be to carry out chemotherapy, thus Shi Zhi doctor comprise the reaction of the order of severity of disease, patient to disease, with the multiple factor basis of treating relevant toxicity, patient age and health etc. on dosage method is kept watch on closely.On the therapeutic outcome basis that utilizes formula I chemical compound to obtain, the initial venoclysis dosage of our predictions when employing dosage regimen every day is about 0.1-100mg/m
2, and be 1-4000mg/m when adopting weekly dosage regimen
2Other dosage all is predictable with changing, and confirms through doctor's guidance.Formula I chemical compound is preferably with venoclysis and oral way administration, preferably with tablet or capsule form administration.Other administration route also is feasible, for example through implant, parenteral (except that intravenously administrable, like intraperitoneal and subcutaneous injection), rectally, intranasal administration, intravaginal administration and percutaneous dosing.
Formula I chemical compound can be used as unique activity chemistry therapeutic agent administration or carries out administration as containing more than the part in the chemotherapy scheme of an antitumor agent.Utilize synergistic chemotherapeutant usually to require every kind of specific medication dosage is reduced, thereby increased the safety range of particular agent.
The oral formulations that contains reactive compound of the present invention can comprise any traditional oral forms, comprises tablet, capsule, cheek form, buccal tablet, lozenge and liquid oral, suspension or solution.Capsule can contain the mixture that reactive compound and inert filler and/or diluent are known the acceptable starch of pharmacy (like corn, Rhizoma Solani tuber osi or tapioca), saccharide, artificial sweetener, powdery cellulose such as crystallization and microcrystalline Cellulose, flour, gelatin, natural gum etc. and useful tablet can and utilize pharmacy acceptable diluent, binding agent, lubricant, disintegrating agent, surface modifier (comprising surfactant), suspending agent or stabilizing agent through traditional compacting, wet system thick method or drying traction therapy, includes but are not limited to: magnesium stearate, stearic acid, Talcum, sodium lauryl sulphate, microcrystalline Cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, arabic gum, xanthan gum, sodium citrate, composition silicate, calcium carbonate, glycine, dextrin, sucrose, sorbitol, calcium hydrogen phosphate, calcium sulfate, lactose, Kaolin, mannitol, sodium chloride, Talcum, dried starch and Powdered saccharide.Preferred surface modifier comprises nonionic and anionic surface modifier.The representative illustration of surface modifier includes but are not limited to: poloxamer 188, geramine, calcium stearate, cetostearyl alcohol, Isosorbide Dinitrate, silica sol, phosphate, sodium lauryl sulphate, Magnesiumaluminumsilicate and triethanolamine. the absorption that oral system standard delay capable of using here or sustained release preparation change reactive compound.Oral formulations also comprises and is included in the water that contains required suitable solubilizing agent or emulsifying agent or the active component in the fruit juice.
In some cases, directly giving chemical compound through air flue with aerosol form also is that we are needed.
Chemical compound of the present invention also can pass through parenteral or intraperitoneal administration.Can be suitable for surfactant such as the blended water of hydroxypropyl cellulose in preparation as the solution or the suspension of these chemical compounds of free alkali or pharmaceutically acceptable salt.Also can glycerol, liquid macrogol and with the mixture of oil in prepare dispersion.Under common storage and application conditions, these preparations contain antiseptic to prevent growth of microorganism.
The medicament forms that is suitable for infusion application comprises aseptic aqueous solution or dispersion and the sterilized powder that is used for temporarily preparing aseptic parenteral solution and dispersion.In all cases, thus these forms must be the aseptic abilities be easy to inject of preserving.It must be stable under preparation and storage requirement, and is stored under the condition that can prevent microorganism such as antibacterial and fungal contamination.Carrier can be and contains dissolving not or disperse medium just like water, ethanol, polyhydric alcohol (like glycerol, propylene glycol and liquid macrogol), their suitable mixture and vegetable oil.For the purpose of content disclosed by the invention, percutaneous dosing is interpreted as all administrations of carrying out through body surface and the body passage that comprises epithelium and mucosal tissue.Such administration can be carried out with lotion, cream, foam, patch, suspension, solution and suppository (rectum and vagina) form through utilizing chemical compound of the present invention or the acceptable salt of its pharmacy.
The specific embodiment
Experimental example 1: The compounds of this invention suppresses ACHN renal carcinoma Study on Growth
1 materials and methods
1.1 experiment material
Female BALB/c-nu/nu nude mouse, 4 ages in week, average weight 14.1g (12.8-15.9) g.The ACHN renal cancer cell line is available from U.S. typical case species preservation centers (ATCC).
1.2 experimental technique
With ACHN kidney cancer cell 2.0 * 10
6It is subcutaneous that/0.2ml is inoculated in back, every nude mice right side, by the body weight numbering 18 nude mouses is divided into medication group and matched group at random.Two groups of body weight do not have significant difference.Rose on the 3rd day the inoculation back, the administration next day of beginning, and the medication group gives formula I chemical compound of the present invention (60mg/kg), and matched group gives The compounds of this invention solvent (3% dehydrated alcohol+97% normal saline).Away from the tumor subcutaneous injection, each every 0.2ml.Observe the mice ordinary circumstance during the administration, the next day measure the mice body weight, the tumor size, gross tumor volume is used formula: V=1/2 * a * b
2, (a is a major diameter, and b is a minor axis).Inoculate the 31st day, disconnected neck is put to death mice, measures gross tumor volume before dissecting, claims that Mus is heavy.The dissection Subcutaneous tumor is also weighed, and cuts mouse lung.FAA (glacial acetic acid+formalin+ethanol) is Subcutaneous tumor and Mus lung fixedly, FFPE.Calculate Mus heavy (Mus weight=band tumor Mus weight-tumor is heavy) once more.The maximum tangent plane HE dyeing of two lung coronalplanes, microscopically (100 times of visuals field) counting lung shifts tuberosity.
1.3 statistical procedures
Tumor weight, volume, Mus are reused the t check between two groups, and the gross tumor volume growth curve is used the SAS covariance analysis, and the lung metastatic nodules is checked with accurate probabilistic method.
2 results
2.1 heavily reaching gross tumor volume, subcutaneous tumors changes
When inoculating the 31st day, two groups of subcutaneous tumors heavily are respectively 648.57 ± 135.68mg and 249.35 ± 79.26mg, and medication group tumor heavily is starkly lower than matched group (p＜0.01).During 31d, two groups of subcutaneous tumors volumes are respectively 339.63 ± 54.74mm
3With 119.46 ± 52.58mm
3(p＜0.01).Two groups of tumor volume-times change sees table 1:
Result of the test shows: the growth of medication group gross tumor volume significantly is lower than matched group.
2.2 lung shifts tuberosity
7 lung metastasis in 9 Mus of matched group, 2 is 1 transfer tuberosity, all the other are 3-5 and shift tuberosity that the medication group does not find that lung shifts tuberosity.Check two groups of differences that significance meaning (p＜0.05) is arranged through accurate probabilistic method.The matched group not only rate of transform is high, and metastatic nodules is also more.
2.3 side effect is observed during the medication
During the medication, each mice is movable good, does not see untoward reaction such as diarrhoea.
2.4 conclusion (of pressure testing):
Formula I chemical compound medication group tumor of the present invention heavily is starkly lower than matched group; Have statistical significance (p＜0.01), the growth of medication group gross tumor volume significantly is lower than matched group, and formula I chemical compound of the present invention has the effect of tangible tumor growth; Particularly suppress the effect of renal carcinoma tumor growth; Formula I chemical compound of the present invention obviously suppresses the lung metastasis rate, and formula I chemical compound of the present invention has lower toxic and side effects.
Claims (10)
1. formula I chemical compound is used to prepare the purposes of treatment tumor of kidney medicine.
2. purposes according to claim 1, wherein, said tumor of kidney is a renal carcinoma.
3. purposes according to claim 1, wherein, said tumor of kidney is a nephroblastoma.
4. purposes according to claim 1, wherein, said tumor of kidney is a renal papillae shape tumor.
5. purposes according to claim 1, wherein, said tumor of kidney is the carcinoma of renal parenchyma.
6. purposes according to claim 1, wherein, said tumor of kidney is a carcinoma of renal pelvis.
7. purposes according to claim 1, wherein, said tumor of kidney is a renal cell carcinoma.
8. purposes according to claim 1, wherein, said tumor of kidney is a renal adenoma.
9. purposes according to claim 1, wherein, said tumor of kidney is a cyst of kidney.
10. purposes according to claim 1, wherein, said tumor of kidney is a renal fibroma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102888033A CN102406645A (en) | 2010-09-20 | 2010-09-20 | Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102888033A CN102406645A (en) | 2010-09-20 | 2010-09-20 | Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102406645A true CN102406645A (en) | 2012-04-11 |
Family
ID=45909185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102888033A Pending CN102406645A (en) | 2010-09-20 | 2010-09-20 | Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406645A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076473A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted pyrimidinyloxy ureas useful as inhibitors of protein kinases |
-
2010
- 2010-09-20 CN CN2010102888033A patent/CN102406645A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076473A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted pyrimidinyloxy ureas useful as inhibitors of protein kinases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107213466B (en) | A kind of column aromatic hydrocarbons compound, preparation method, pharmaceutical composition and purposes | |
| CN101277707A (en) | Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis | |
| CN104758277A (en) | Uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer | |
| CN102698271B (en) | Hypoglycemic drug composition and application thereof | |
| CN100584835C (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| JP2008528640A (en) | Antitumor synergistic pharmaceutical composition of baicalein and baicalin | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN1282458C (en) | Cefadroxil dry suspension and preparing method | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN102406645A (en) | Purpose of arylurea derivative in preparing medicine for treating kidney neoplasms | |
| CN110200960A (en) | Genistein is preparing the purposes in the drug for preventing or treating African swine fever | |
| CN102406647A (en) | New application of aromatic urea derivatives in preparation of medicines for treating renal tumor | |
| CN105232527A (en) | Application of medicine containing catechin to preparation of medicines for prevention and/or treatment of cancers | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN102961342A (en) | Nanoscale capecitabine and preparation method thereof | |
| CN102068415A (en) | Carbazole sulfonamide anti-tumor medicine dispersible tablets and preparation method thereof | |
| CN106063788A (en) | Phillyrin, phillyrin derivant, phillyrin are alleviated or/and the application in medicine or health product is vomitted in treatment in preparation with phillygenol compositions | |
| CN101897929B (en) | Improved composition as well as preparation method and application thereof | |
| CN1857297A (en) | Medicine composition for treating microcirculation dysfunction and its preparing method | |
| CN104208707B (en) | Preparation method of folic acid modified Pluronic P85 copolymer and application of folic acid modified Pluronic P85 copolymer in 5-fluorouracil nano drug | |
| CN101984961B (en) | Furanodiene-containing medicinal composition, technology for preparing preparation thereof and medicinal use thereof | |
| CN102885778A (en) | Active carbon paclitaxel nano-drug delivery system, and preparation method and application thereof | |
| CN102319438A (en) | The preparation and preparation method thereof and the purposes that comprise the genistein clathrate | |
| CN102512409A (en) | Medical preparation containing levocarnitine and dihydroxybenzenesulphonic acid salt and preparation method of medical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120411 |